Releasing the brake: CTLA-4 loss turbocharges CAR T cells
- PMID: 37820579
- DOI: 10.1016/j.immuni.2023.09.006
Releasing the brake: CTLA-4 loss turbocharges CAR T cells
Abstract
Immune checkpoint receptor-induced T cell dysfunction is a major cause of CAR T cell treatment failure. In this issue, Agarwal et al. report that CRISPR/Cas9 deletion of CTLA4, but not PDCD1 or CTLA4 and PDCD1, enhances CD28 signaling, restoring fitness and antitumor function of CAR T cells, including those derived from patients who failed CAR T cell therapy.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.G. has consulting agreements with Lyell Immunopharma, is on the scientific advisory boards of Poseida Therapeutics and Kiromic, and is a stockholder of Poseida Therapeutics. The figure was created with BioRender.com.
Comment on
-
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells.Immunity. 2023 Oct 10;56(10):2388-2407.e9. doi: 10.1016/j.immuni.2023.09.001. Epub 2023 Sep 29. Immunity. 2023. PMID: 37776850 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
